Volume 4.09 | Mar 8

Prostate Cell News 4.09 March 8, 2013
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
TOP STORY
Regulation of Protein Translation and c-Jun Expression by Prostate Tumor Overexpressed 1
Scientists showed that prostate tumor overexpressed-1 (PTOV1) interacts directly with receptor of activated protein C kinase 1, a regulator of protein kinase C and Jun signaling and also a component of the 40S ribosome. Consistent with this interaction, PTOV1 was associated with ribosomes and its overexpression promoted global protein synthesis in prostate cancer cells and COS-7 fibroblasts in a mTORC1-dependent manner. [Oncogene] Abstract

Apply Now: Mammary Stem Cells Training Course (June 8-9 2013) in Vancouver, Canada.
PUBLICATIONS (Ranked by impact factor of the journal)

LABORATORY RESEARCH

Downregulation of Dickkopf-3 Disrupts Prostate Acinar Morphogenesis through TGF-β/Smad Signaling
To gain insight into the function of Dickkopf-3 (Dkk-3) in the prostate, researchers compared the prostates of Dkk3 null mice with those of control littermates. They found increased proliferation of prostate epithelial cells in the mutant mice and changes in prostate tissue organization. [J Cell Sci] Abstract

The Transcription Factor SPDEF Is Required for E-Cadherin Expression in Prostate Cancer Cells
The authors evaluated the relationship between SAM Pointed Domain ETS transcription Factor (SPDEF) and E-Cadherin expression in an effort to better understand the mechanism of action of SPDEF in prostate tumor-cell invasion and metastasis. [J Biol Chem] Abstract

ARF Represses Androgen Receptor Transactivation in Prostate Cancer
Scientists provide evidence that p14 alternative reading frame (ARF) physically interacts with androgen receptor (AR) and functions as an AR corespressor in both an androgen-dependent and androgen-independent manner. [Mol Endocrinol] Abstract

Expression of Lysophosphatidic Acid Receptor 1 and Relation with Cell Proliferation, Apoptosis, and Angiogenesis on Preneoplastic Changes Induced by Cadmium Chloride in the Rat Ventral Prostate
Researchers evaluated the immunoexpression of lysophosphatidic acid, cell proliferation, apoptosis, and angiogenesis markers in preneoplastic lesions induced with cadmium chloride in rat prostate. [PLoS One]
Full Article

Overexpression of a Key Regulator of Lipid Homeostasis, Scap, Promotes Respiration in Prostate Cancer Cells
Investigators examined LNCaP cells overexpressing the sterol regulatory element-binding protein 2 (SREBP-2) regulator, Scap; although having higher SREBP-2 activity, these cells displayed higher respiration. [FEBS Lett] Abstract

miR-152 Controls Migration and Invasive Potential by Targeting TGFα in Prostate Cancer Cell Lines
Aberrant MicroRNA-152 (miR-152) expression has been frequently reported in various malignant tumors. However, the mechanism of miR-152 in prostate cancer (PCa) remains unclear. Researchers aimed to determine the function of miR-152 in PCa cells and identify the novel molecular targets regulated by miR-152. [Prostate] Abstract

Noradrenaline Induces Binding of Clathrin Light Chain A to α1-Adrenoceptors in the Human Prostate
The authors investigated the expression and α1-adrenoceptor binding of clathrins, caveolin, and their cofactors in the human prostate. [Prostate] Abstract

CLINICAL RESEARCH

Retrospective Evaluation Reveals that Long-term Androgen Deprivation Therapy Improves Cause-Specific and Overall Survival in the Setting of Dose-Escalated Radiation for High-Risk Prostate Cancer
The relationship between androgen deprivation therapy use and duration with biochemical failure, metastatic failure, prostate cancer-specific mortality, non-prostate cancer death, and overall survival was assessed as a function of pretreatment characteristics, comorbid medical illness, and treatment using Fine and Gray’s cumulative incidence methodology. [Int J Radiat Oncol Biol Phys] Abstract

Long-Term Follow-Up of a Phase II Trial of Chemotherapy plus Hormone Therapy for Biochemical Relapse after Definitive Local Therapy for Prostate Cancer
Treatment was four cycles of docetaxel every three weeks and estramustine three times a day followed by 15 months of goserelin acetate/bicalutamide. The primary endpoint was the proportion with prostate-specific antigen <0.1 with recovered testosterone five years after completion of therapy. [Urology] Abstract

View Lectures, Tools, Protocols and Other Resources on the Human Immunology Portal (www.humanimmunologyportal.com)

REVIEWS
Validation and Clinical Utility of Prostate Cancer Biomarkers
The authors discuss the framework for the development of biomarkers for castration-resistant prostate cancer, including different categories and contexts of use. They also highlight the requirements of analytical validation, the sequence of trials needed for clinical validation and regulatory approval, and the future outlook for imaging and circulating tumor cell biomarkers. [Nat Rev Clin Oncol] Abstract
INDUSTRY NEWS

Nymox Provides Current Phase II Prostate Cancer Clinical Trial Update
Nymox Pharmaceutical Corporation provided an update on U.S. Phase II prostate cancer clinical trial activities for NX-1207, the company’s new investigational drug being tested for early stage prostate cancer. [Nymox Pharmaceutical Corporation] Press Release

DCVax®-Direct Phase I/II Trial for All Inoperable Solid Tumors Is Expected to Produce Ongoing Results in 2013
Northwest Biotherapeutics, a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that its Phase I/II DCVax-Direct clinical trial for all inoperable solid tumor cancers is planned to begin within approximately the next sixty days. [Northwest Biotherapeutics, Inc.]
Press Release

POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS

NEW Targeting Cancer Drug Resistance
May 28-31, 2013
Chicago, United States

Visit
our events page to see a complete list of events in the prostate cell community.

JOB OPPORTUNITIES

PhD Studentship – Investigation into Chemokine Receptor Induced Cell Migration (University of East Anglia)

Postdoctoral Position – Genetic and Epigenetic Mechanisms of Prostate Cancer (Northwestern University Feinberg School of Medicine)

Assistant or Associate Professor – Cancer Biology (Yale School of Medicine)

Postdoctoral Position – Advanced Prostate Cancer (Weill Cornell Medical College)

Postdoctoral Position – Aggressiveness or Progression in Prostate Cancer (Roswell Park Cancer Institute)

PhD Studentship – Detection of Novel Prostate Cancer Biomarkers (University of Bath)

PhD Studentship – Multi-Compartment Magnetic Resonance Imaging of Prostate Cancer (University of East Anglia)


Recruit Top Talent : Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us